You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the LOCAMETZ (gallium ga-68 gozetotide) Drug Profile, 2024 PDF Report in the Report Store ~

locametz Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Locametz, and when can generic versions of Locametz launch?

Locametz is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in fifteen countries.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.

DrugPatentWatch® Generic Entry Outlook for Locametz

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for locametz
International Patents:34
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for locametz
What excipients (inactive ingredients) are in locametz?locametz excipients list
DailyMed Link:locametz at DailyMed
Drug patent expirations by year for locametz
Drug Prices for locametz

See drug prices for locametz

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for locametz
Generic Entry Date for locametz*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for locametz

locametz is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of locametz is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting locametz

PSMA binding ligand-linker conjugates and methods for using
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER

FDA Regulatory Exclusivity protecting locametz

NEW PRODUCT
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis LOCAMETZ gallium ga-68 gozetotide POWDER;INTRAVENOUS 215841-001 Mar 23, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Novartis LOCAMETZ gallium ga-68 gozetotide POWDER;INTRAVENOUS 215841-001 Mar 23, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for locametz

When does loss-of-exclusivity occur for locametz?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08289108
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 96627
Estimated Expiration: ⤷  Try a Trial

China

Patent: 2014956
Estimated Expiration: ⤷  Try a Trial

Patent: 4873982
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 87965
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 87965
Estimated Expiration: ⤷  Try a Trial

Patent: 88086
Estimated Expiration: ⤷  Try a Trial

Patent: 56403
Estimated Expiration: ⤷  Try a Trial

Patent: 31380
Estimated Expiration: ⤷  Try a Trial

Patent: 38298
Estimated Expiration: ⤷  Try a Trial

Patent: 58347
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 12588
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 47200
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 3998
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 02237
Estimated Expiration: ⤷  Try a Trial

Patent: 96479
Estimated Expiration: ⤷  Try a Trial

Patent: 25690
Estimated Expiration: ⤷  Try a Trial

Patent: 38118
Estimated Expiration: ⤷  Try a Trial

Patent: 79355
Estimated Expiration: ⤷  Try a Trial

Patent: 10536790
Estimated Expiration: ⤷  Try a Trial

Patent: 14221779
Estimated Expiration: ⤷  Try a Trial

Patent: 16153410
Estimated Expiration: ⤷  Try a Trial

Patent: 18058864
Estimated Expiration: ⤷  Try a Trial

Patent: 18150350
Estimated Expiration: ⤷  Try a Trial

Patent: 20073472
Estimated Expiration: ⤷  Try a Trial

Patent: 21075561
Estimated Expiration: ⤷  Try a Trial

Patent: 22110118
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 3931
Estimated Expiration: ⤷  Try a Trial

Patent: 0085
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 87965
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 87965
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 87965
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 68224
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering locametz around the world.

Country Patent Number Title Estimated Expiration
Japan 2018150350 PSMA結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) ⤷  Try a Trial
Japan 2010536790 ⤷  Try a Trial
Japan 2016153410 PSMA結合性リガンド−リンカー結合体及び使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) ⤷  Try a Trial
European Patent Office 3858347 CONJUGUÉS LIGAND-LIEUR DE LIAISON AU PSMA ET PROCÉDÉS POUR UTILISER CEUX-CI (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING) ⤷  Try a Trial
Hong Kong 1212588 結合配體-接頭綴合物及其使用方法 (PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PSMA -) ⤷  Try a Trial
Japan 2022110118 PSMA結合性リガンド-リンカー結合体及び使用方法 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.